Navigation Links
Scripps Research scientists find two compounds that lay the foundation for a new class of AIDS drug
Date:2/3/2010

sites on the molecule.

To overcome this problem, the team "plugged up" the active site with a known inhibitor so that the screen would identify only fragments that bound to other regions of the protease. Perryman noted that this innovative protocol could be applied to similar work on many different disease-causing agents, especially those that have developed drug resistance.

Using the new method for crystallographic screening, the team found two "hits"fragments 2-methylcyclohexanol and indole-6-carboxylic acid. The scientists used additional x-ray crystallographic experiments to confirm first that the fragments indeed bound to novel sites in the protease and second that these fragments change the structural preferences of protease.

"Since these fragments are very small, we wouldn't expect them to be potent inhibitors by themselves," said Perryman. "But it's the beginning of a process where we can try to use these little fragments to build up to a real potent inhibitor. The study validates our predictions and lays the structural foundation for the development of new classes of anti-AIDS drugs."


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Scripps scientists discover fluorescence in key marine creature
2. Scripps research team blocks bacterial communication system to prevent deadly staph infections
3. Scripps scientists develop new tests that identify lethal prion strains quickly and accurately
4. Scripps Research discovery leads to broad potential applications in CovX-Pfizer deal
5. Scripps expedition provides new baseline for coral reef conservation
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. Fishing throws targeted species off balance, Scripps study shows
8. Scripps Oceanography Research pegs ID of red tide killer
9. Scripps Research Institute awarded patent for remarkable chemical technology
10. Scripps research scientists reveal key structure from ebola virus
11. Scripps study sets high economic value on threatened Mexican mangroves
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/29/2014)... suggesting air pollutants released by unconventional oil and gas ... is published today in the open access journal ... and formaldehyde were found. The study is the first ... live near production sites and could be used to ... gas come from reserves that do not readily flow ...
(Date:10/29/2014)... (October 29, 2014, Beaverton, OR) New research ... 11th International Conference in Houston, TX showed for ... eliminate HPV infection in women using a readily ... The study, presented by Dr. Judith A. Smith, ... Gynecology and Reproductive Sciences at The University of ...
(Date:10/29/2014)... their food, but they also need protection from its harmful ... of molecules in plants that shields them from sun damage. ... American Chemical Society , one team reports on the mechanics ... and colleagues at Purdue University note that the harsh ultraviolet ... to plant DNA and, as a result, hinder plant growth. ...
Breaking Biology News(10 mins):Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... -- New research is shedding light on the preferred habitat ... often overlooked species in Arctic marine food webs. Squid, ... important role as prey in Arctic waters for species such ... Kathleen Gardiner, a PhD candidate in the Biological Sciences Department ...
... -- Montana State University historian Timothy J. LeCain recently ... best new book in environmental history. The ... that Wired America and Scarred the Planet," tells the ... Berkeley Pit in Butte, Mont., and the Bingham ...
... 7, 2010) More than 1600 genetics researchers who use ... to study basic aspects of biology ranging from memory to ... underlie evolution, will be gathering in Washington, DC, for the ... Genetics Society of America, and beginning this evening at the ...
Cached Biology News:Habitat of elusive Northern squid documented by researcher 2Montana State University historian wins prize for book on Montana, Utah copper mines 2Drosophilists fly into DC for 51st Annual Drosophila Research Conference 2
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Ardelyx, ... biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic ... quarter 2014 financial results on Thursday, November 6, ... will host a live conference call and webcast ... results and provide a business update. ...
(Date:10/30/2014)... 30, 2014 On October 26th ... Showcase in Chicago, leading applied stem cell research ... Wade McKenna presented talks on New Techniques for ... Applications For Stem Cells. , Dr. Riordan focused ... the properties of AlphaGEMS that include: wound healing; ...
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... 2014 Avure Technologies celebrates a year of ... member of its fleet of high volume High Pressure Processing ... as we return to PackExpo this year, which is where ... Vegas,” said Jeff Williams, CEO at Avure. “Sales of the ... to be meeting the challenges of market demand for higher ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... EMERYVILLE, Calif., Sept. 17 Neurobiological Technologies, Inc. (Nasdaq: ... 15, 2009, it received a letter from The Nasdaq Stock ... has closed below $1.00 per share for 30 consecutive business ... $1.00 per share is a deficiency under Nasdaq,s requirements for ...
... , , EAST HANOVER, N.J., ... approved Valturna(R) (aliskiren and valsartan) tablets, the first and only medicine ... as the renin angiotensin aldosterone system (RAAS), an important regulator of ... indicated for the treatment of high blood pressure in patients not ...
... , ABBOTT PARK, Ill., Sept. 17 The board of directors ... of 40 cents per share. , , This marks ... The cash dividend is payable Nov. 15, 2009, to shareholders of record at ... Abbott has increased its dividend payout for 37 consecutive years - including an ...
Cached Biology Technology:Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 2Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 3Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 4Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 5Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 6Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure 7